Highly prevalent colorectal cancer-infiltrating LAP + Foxp3 - T cells exhibit more potent immunosuppressive activity than Foxp3 + regulatory T cells

Mucosal Immunology

Volumn 7, Issue 2, 2014, Pages 428-439

  Scurr, M ^a   Ladell, K ^a   Besneux, M ^a   Christian, A ^b   Hockey, T ^b   Smart, K ^a   Bridgeman, H ^a   Hargest, R ^b   Phillips, S ^b   Davies, M ^b   Price, D ^a   Gallimore, A ^a   Godkin, A ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD103 ANTIGEN; CD39 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; LATENCY ASSOCIATED PEPTIDE; LYMPHOCYTE ACTIVATION GENE 3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; COLORECTAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; INTEGRIN ALPHA CHAINS; INTERLEUKIN-10; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84895168217     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.62     Document Type: Article

References (55)

1. Jemal, A. et al. Global cancer statistics. CA Cancer JClin 61, 69-90 (2011).
2. Schreiber,R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
3. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
4. Scarlett, U.K. et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 203, 495-506 (2012).
5. Fujio, K., Okamura, T. &Yamamoto,K. The family of IL-10-secretingCD4+ T cells. Adv. Immunol. 105, 99-130 (2010).
6. Wrzesinski, S.H.,Wan, Y.Y. & Flavell, R.A. Transforming growth factor-beta and the immune response: Implications for anticancer therapy. Clin. Cancer Res. 13, 5262-5270 (2007).
7. Ellis, L.M. & Hicklin, D.J. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591 (2008).
8. Munn, D.H. & Mellor, A.L. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J. Clin. Invest. 117, 1147-1154 (2007).
9. Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828-835 (2007).
10. Nishikawa, H. & Sakaguchi, S. Regulatory Tcells in tumor immunity. Int. J. Cancer 127, 759-767 (2010).
11. Gallimore, A. & Godkin, A. Regulatory T cells and tumour immunity-observations in mice and men. Immunology 123, 157-163 (2008).
12. Liang, B. et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol. 180, 5916-5926 (2008).
13. Shevach, E.M. Biological functions of regulatory Tcells. Adv. Immunol. 112, 137-176 (2011).
14. Betts, G.J., Clarke, S.L., Richards, H.E., Godkin, A.J. & Gallimore, A.M. Regulating the immune response to tumours. Adv. Drug Deliv. Rev. 58, 948-961 (2006).
15. Clarke, S.L. et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 1, e129 (2006).
16. Betts, G. et al. Suppression of tumour-specific CD4+ Tcells by regulatory Tcells is associated with progression of human colorectal cancer. Gut 61, 1163-1171 (2012).
17. Frey, D.M. et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 126, 2635-2643 (2010).
18. Salama, P. et al. Tumor-infiltrating FOXP3+ Tregulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27, 186-192 (2009).
19. Hindley, J.P. etal.Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res. 71, 736-746 (2011).
20. Thornton, A.M. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184, 3433-3441 (2010).
21. Himmel, M.E.,MacDonald, K.G., Garcia, R.V., Steiner, T.S. & Levings, M.K. Helios+ and Helios-cells coexist within the natural FOXP3+ Tregulatory cell subset in humans. J. Immunol. 190, 2001-2008 (2013).
22. Akimova, T., Beier, U.H., Wang, L., Levine, M.H. & Hancock, W.W. Helios expression is a marker of T cell activation and proliferation. PLoS One 6, e24226 (2011).
23. Chauhan, S.K., Saban, D.R., Lee, H.K. & Dana, R. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J. Immunol. 182, 148-153 (2009).
24. Barnes, M.J. & Powrie, F. Regulatory T cells reinforce intestinal homeostasis. Immunity 31, 401-411 (2009).
25. Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209 (1713-1722), S1711-S1719 (2012).
26. Mahajan, S. et al. The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells. Eur. J. Immunol. 37, 1796-1808 (2007).
27. Strauss, L. et al. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: Implications and impact on tumor-mediated immune suppression. J. Immunol. 180, 2967-2980 (2008).
28. Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ Tcells expressing the FoxP3 transcription factor. Immunity 30, 899-911 (2009).
29. Kmieciak, M. et al. Human Tcells expressCD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J. Transl. Med. 7, 89 (2009).
30. Schneider, H. et al. Reversal of the TCR stop signal by CTLA-4. Science 313, 1972-1975 (2006).
31. Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
32. Huang, C.T. et al. Role of LAG-3 in regulatory Tcells. Immunity 21, 503-513 (2004).
33. Woo, S.R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012).
34. Gagliani, N. et al. Coexpression ofCD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19, 739-746 (2013).
35. Schon, M.P. et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J. Immunol. 162, 6641-6649 (1999).
36. Lehmann, J. et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25-regulatory T cells. Proc. Natl. Acad. Sci. USA 99, 13031-13036 (2002).
37. Svensson, H. et al. Accumulation of CCR4CTLA-4 FOXP3CD25(hi) regulatory Tcells in colon adenocarcinomas correlate to reduced activation of conventional T cells. PLoS One 7, e30695 (2012).
38. Gandhi, R. et al. Cutting edge: Human latency-associated peptide + T cells: A novel regulatory T cell subset. J. Immunol. 184, 4620-4624 (2010).
39. Mahalingam, J. et al. LAP+CD4+ Tcells are suppressors accumulated in the tumor sites and associated with progression of colorectal cancer. Clin Cancer Res. 18, 5224-5233 (2012).
40. Saito, T. et al. Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta. J. Biol. Chem. 276, 11469-11472 (2001).
41. Min, B. et al. Gut flora antigens are not important in the maintenance of regulatory T cell heterogeneity and homeostasis. Eur. J. Immunol. 37, 1916-1923 (2007).
42. Vukmanovic-Stejic, M. et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116, 2423-2433 (2006).
43. Restifo, N.P., Dudley,M.E. & Rosenberg, S.A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
44. Curiel, T.J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
45. Ladoire, S., Martin, F. & Ghiringhelli, F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol. Immunother. 60, 909-918 (2011).
46. Morgan, M.E. et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum. Immunol. 66, 13-20 (2005).
47. Ziegler, S.F. FOXP3: Not just for regulatory Tcells anymore. Eur. J. Immunol. 37, 21-23 (2007).
48. Grosso, J.F. et al. LAG-3 regulates CD8+ Tcell accumulation and effector function in murine self-and tumor-tolerance systems. J. Clin. Invest. 117, 3383-3392 (2007).
49. Matsuzaki, J. et al. Tumor-infiltrating NY-ESO-1-specific CD8+ Tcells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 107, 7875-7880 (2010).
50. Gandhi, M.K. et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108, 2280-2289 (2006).
51. Donkor, M.K. et al. Tcell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 35, 123-134 (2011).
52. Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P. & Yamaguchi, T. Regulatory T cells: How do they suppress immune responses+. Int. Immunol. 21, 1105-1111 (2009).
53. Whiteside, T.L., Miescher, S., MacDonald, H.R. & Von Fliedner, V. Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J. Immunol. Methods 90, 221-233 (1986).
54. McMurchy, A.N. & Levings, M.K. Suppression assays with human T regulatory cells: A technical guide. Eur. J. Immunol. 42, 27-34 (2012).
55. Roederer,M., Nozzi, J.L. & Nason, M.C. SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79, 167-174 (2011).